Use of agents which inhibit connective tissue growth factor (CTGF) binding and signaling via the TrkA/p75NTR receptor complex for the prevention and treatment of CTGF-mediated ocular disorders

Number of patents in Portfolio can not be more than 2000

United States of America Patent

APP PUB NO 20060275797A1
SERIAL NO

11384638

Stats

ATTORNEY / AGENT: (SPONSORED)

Importance

Loading Importance Indicators... loading....

Abstract

See full text

The present invention provides a method for lowering intraocular pressure and providing neuroprotection to a patient in need thereof by administering a therapeutically effective amount of at least one agent that inhibits binding and/or signaling of connective tissue growth factor (CTGF) via the TrkA/p75.sup.NTR receptor complex.

Loading the Abstract Image... loading....

First Claim

See full text

Family

Loading Family data... loading....

Patent Owner(s)

Patent OwnerAddress
ALCON MANUFACTURING LTD6201 SOUTH FREEWAY FORT WORTH TX 76134

International Classification(s)

Inventor(s)

Inventor Name Address # of filed Patents Total Citations
Clark, Abbot F Arlington, TX 126 1394
Jacobson, Nasreen Fort Worth, TX 8 17
Shepard, Allan R Fort Worth, TX 28 243

Cited Art Landscape

Load Citation

Patent Citation Ranking

Forward Cite Landscape

Load Citation